Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Coghill

Showing results (131-140 of 230) with videos related to

Pageof 23
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 22, 2013
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorderDavid Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
The Australian and New Zealand Journal of Psychiatry|October 27, 2023
Age at diagnosis and diagnostic delay across attention-deficit hyperactivity and autism spectrumsRachael Knott, Olivia J Mellahn, Jeggan Tiego, et al.
Journal of Attention Disorders|October 13, 2020
Social and Economic Costs of Attention-Deficit/Hyperactivity Disorder Across the LifespanEmma Sciberras, Jared Streatfeild, Tristan Ceccato, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|January 18, 2023
Practitioner Review: It's time to bridge the gap - understanding the unmet needs of consumers with attention-deficit/hyperactivity disorder - a systematic review and recommendationsMatthew Bisset, Louise E Brown, Sampada Bhide, et al.
The Lancet. Child & Adolescent Health|May 26, 2020
Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series studyKenneth K C Man, Wallis C Y Lau, David Coghill, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 1, 2024
AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential MedicinesSamuele Cortese, David Coghill, Gregory W Mattingly, et al.
CNS Drugs|August 21, 2013
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb studyRalf W Dittmann, Esther Cardo, Peter Nagy, et al.
JAMA Psychiatry|June 25, 2025
Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over TimeLin Li, David Coghill, Arvid Sjölander, et al.
BMC Psychiatry|August 27, 2016
Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD networkSusan Young, Marios Adamou, Philip Asherson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|March 3, 2009
Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adultsSuzanne McCarthy, Philip Asherson, David Coghill, et al.
Pageof 23

Showing results (131-140 of 230) with videos related to

Sort By:
Pageof 23
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 22, 2013
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorderDavid Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
The Australian and New Zealand Journal of Psychiatry|October 27, 2023
Age at diagnosis and diagnostic delay across attention-deficit hyperactivity and autism spectrumsRachael Knott, Olivia J Mellahn, Jeggan Tiego, et al.
Journal of Attention Disorders|October 13, 2020
Social and Economic Costs of Attention-Deficit/Hyperactivity Disorder Across the LifespanEmma Sciberras, Jared Streatfeild, Tristan Ceccato, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|January 18, 2023
Practitioner Review: It's time to bridge the gap - understanding the unmet needs of consumers with attention-deficit/hyperactivity disorder - a systematic review and recommendationsMatthew Bisset, Louise E Brown, Sampada Bhide, et al.
The Lancet. Child & Adolescent Health|May 26, 2020
Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series studyKenneth K C Man, Wallis C Y Lau, David Coghill, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 1, 2024
AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential MedicinesSamuele Cortese, David Coghill, Gregory W Mattingly, et al.
CNS Drugs|August 21, 2013
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb studyRalf W Dittmann, Esther Cardo, Peter Nagy, et al.
JAMA Psychiatry|June 25, 2025
Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over TimeLin Li, David Coghill, Arvid Sjölander, et al.
BMC Psychiatry|August 27, 2016
Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD networkSusan Young, Marios Adamou, Philip Asherson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|March 3, 2009
Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adultsSuzanne McCarthy, Philip Asherson, David Coghill, et al.
Pageof 23